Jim Simons Immatics N.V. Transaction History

Renaissance Technologies LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$6.0 - $9.37 $152,388 - $237,979	-25,398 Reduced 41.1%	36,400 $317,000
Q1 2022 May 13, 2022	BUY	$6.64 - $12.85 $61,074 - $118,194	9,198 Added 17.49%	61,798 $494,000
Q4 2021 Feb 11, 2022	BUY	$10.81 - $14.38 $452,582 - $602,047	41,867 Added 390.08%	52,600 $707,000
Q3 2021 Nov 12, 2021	SELL	$11.58 - $15.46 $684,100 - $913,314	-59,076 Reduced 84.63%	10,733 $140,000
Q2 2021 Aug 13, 2021	BUY	$10.43 - $12.81 $237,897 - $292,183	22,809 Added 48.53%	69,809 $810,000
Q1 2021 May 13, 2021	BUY	$10.24 - $14.6 $481,280 - $686,200	47,000 New	47,000 $527,000

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $623M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.